Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection

Publikation

Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection

Wissenschaftlicher Artikel/Review - 11.07.2013

Metzner Karin J, Aubert Vincent, Furrer Hansjakob, Battegay Manuel, Vernazza Pietro, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Weber Rainer, Günthard Huldrych F, Klimkait Thomas, Yerly Sabine, Böni Jürg, Scherrer Alexandra U, Preiswerk Benjamin, Joos Beda, von Wyl Viktor, Leemann Christine, Rieder Philip, Braun Dominique, Grube Christina, Kuster Herbert, Swiss HIV Cohort Study

Zitation

Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013; 208:1102-12.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Infect Dis 2013; 208

Veröffentlichungsdatum

11.07.2013

eISSN (Online)

1537-6613

Seiten

1102-12

Kurzbeschreibung/Zielsetzung

BACKGROUND
Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants (MVs) are present in some antiretroviral therapy (ART)-naive patients. They may result from de novo mutagenesis or transmission. To date, the latter has not been proven.

METHODS
MVs were quantified by allele-specific polymerase chain reaction in 204 acute or recent seroconverters from the Zurich Primary HIV Infection study and 382 ART-naive, chronically infected patients. Phylogenetic analyses identified transmission clusters.

RESULTS
Three lines of evidence were observed in support of transmission of MVs. First, potential transmitters were identified for 12 of 16 acute or recent seroconverters harboring M184V MVs. These variants were also detected in plasma and/or peripheral blood mononuclear cells at the estimated time of transmission in 3 of 4 potential transmitters who experienced virological failure accompanied by the selection of the M184V mutation before transmission. Second, prevalence between MVs harboring the frequent mutation M184V and the particularly uncommon integrase mutation N155H differed highly significantly in acute or recent seroconverters (8.2% vs 0.5%; P < .001). Third, the prevalence of less-fit M184V MVs is significantly higher in acutely or recently than in chronically HIV-1-infected patients (8.2% vs 2.5%; P = .004).

CONCLUSIONS
Drug-resistant HIV-1 MVs can be transmitted. To what extent the origin-transmission vs sporadic appearance-of these variants determines their impact on ART needs to be further explored.